Markets:

Overview

News

Currencies

International

Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

9.935 +1.065 (+12.01%)

Streaming Delayed Price Updated: 3:56 PM EDT, Jun 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm

July 28, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

July 28, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

July 28, 2025

From Pomerantz LLP

Via GlobeNewswire

From Shriram Properties, Havells To Vesuvius: SEBI RA Sees 15% To 30% Upside In These Six Stocks ↗

July 22, 2025

Via Stocktwits

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf

July 28, 2025

From Grabar Law Office

Via GlobeNewswire

REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc.

July 28, 2025

From Robbins LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)

July 28, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

July 27, 2025

From Grabar Law Office

Via GlobeNewswire

Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets ↗

July 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline

July 25, 2025

From Bleichmar Fonti & Auld LLP

Via Business Wire

Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL

July 25, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

July 24, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 24, 2025

From The Schall Law Firm

Via Business Wire

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL

July 24, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

July 23, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation Against Replimune Group, Inc. (REPL) on Behalf of Investors

July 23, 2025

From Kirby McInerney LLP

Via GlobeNewswire

Which stocks are experiencing notable movement on Wednesday? ↗

July 23, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Via Chartmill

This Centene Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

July 23, 2025

Via Benzinga

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

July 22, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Which stocks are experiencing notable movement on Tuesday? ↗

July 22, 2025

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

July 22, 2025

From Bleichmar Fonti & Auld LLP

Via Business Wire

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗

July 22, 2025

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 22, 2025

Via Benzinga

Nasdaq Falls Over 100 Points; Coca-Cola Posts Upbeat Earnings ↗

July 22, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

July 22, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation – REPL

July 22, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Gapping stocks in Tuesday's session ↗

July 22, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

US Stocks Mixed; General Motors Shares Fall After Q2 Results ↗

July 22, 2025

Via Benzinga

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks ↗

July 22, 2025

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Via Benzinga

Which stocks are moving before the opening bell on Tuesday? ↗

July 22, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.